Evaluation of the safety and efficacy of the Cobra PzF NanoCoated coronary stent in routine, consecutive, prospective, and high‐risk patients: The e‐Cobra study

Abstract

Background The Cobra PzF coronary stent is cobalt chromium with flat thin struts, nano‐coated with Polyzene‐F that enhance rapid reendothelialization and reduce the risk of stent thrombosis and restenosis. It is designed to overcome shortfalls of BMS and DES in patients requiring short DAPT duration. Aims To report procedural and 1‐year clinical outcomes following Cobra PzF stent implantation in routine practice PCI. Methods e‐Cobra registry is a multicenter prospective study to evaluate Cobra PzF stent in routine practice in patients deemed appropriate for short DAPT after PCI. The primary endpoint was MACE rate at 12 months (Cardiac death, MI, TLR). The secondary endpoint was definite stent thrombosis at 12 months. Results Among 940 patients (72% men, 72.8 ± 13.4 years) with multiple co‐morbidities, 47% had acute coronary syndromes, and 62% were defined as high bleeding risk. A total of 1,229 lesions were treated with 1,314 stents. 36% of patients had lesion type B2 or C classification. Angiographic success was achieved in all cases. One‐year follow‐up was available for 97% of patients. The primary endpoint occurred in 9.0% of patients, including cardiac death 3.7%, MI 4.8%, and TLR 4.3%. Definite stent thrombosis occurred in six out of 915 (0.7%). Conclusion The Cobra PzF stent was safe and effective in routine practice patients and seems feasible in situations when short DAPT or Mono Antiplatelet Therapy (MAPT) is needed. One‐year follow‐up was associated with satisfactory clinical outcomes and validate previously reported data.

COBRA PzF™ Coronary Stent in Clinical and Preclinical Studies: Setting the Stage for New Antithrombotic strategies?

“…Recently, the multicenter prospective e-COBRA study evaluated safety and efficacy of the COBRA PzF stent in routine clinical practice in patients deemed appropriate for shorter duration of DAPT [ 41 ]. The primary end point was MACE (cardiac death, myocardial infarction and target lesion revascularization) at 12 months, the secondary end point was definite stent thrombosis at 12 months.…”

Biofunctionalization of cardiovascular stents to induce endothelialization: Implications for in- stent thrombosis in diabetes

“…-Clinical studies: 1-year follow up showed that the stent performance is satisfactory and confirmed clinical efficacy and safety (Maillard et al, 2021).…”

“…Target vessel failure increased form 11.5% at 9 months to 17.4% at 5 years (Cutlip et al, 2022). (Koppara et al, 2016;Hiroyuki et al, 2019;Maillard et al, 2021;Cutlip et al, 2022;Cornelissen et al, 2022) In vivo studies CoCr A homing peptide for endothelial colony forming cell (WKYMVm)…”

Effects of Simulated COVID-19 Cytokine Storm on Stent Thrombogenicity

“…Based on a CoCr alloy, COBRA-PzF has a nano-thin coating of poly-bis(trifluoroethoxy)phosphazene (Polyzene-F or PzF) which has been shown to preferentially adsorb albumin instead of coagulation-stimulating proteins [ 29 ]. Less platelet adhesion was observed in COBRA-PzF as compared to conventional drug-eluting stents (DES) in a pig shunt study [ 30 ], and clinical studies reported low incidences of ST and spontaneous MI [ [31] , [32] , [33] , [34] ]. On the other hand, hydrophilic polymer surfaces, such as BioLinx in Resolute Onyx, have been suggested to have superior biocompatibility compared with hydrophobic polymer coatings, mostly because they do not induce monocyte adhesion [ 35 ].…”